

Estimate change	
TP change	
Rating change	

Bloomberg	COFORGE IN
Equity Shares (m)	334
M.Cap.(INRb)/(USDb)	560.7 / 6.5
52-Week Range (INR)	2005 / 1120
1, 6, 12 Rel. Per (%)	-10/-18/30
12M Avg Val (INR M)	4182

Financials & Valuations (INR b)

Y/E Mar	FY25	FY26E	FY27E
Sales	120.5	165.4	200.9
EBIT Margin (%)	13.0	13.5	14.0
PAT	8.4	15.0	19.9
EPS (INR)	30.2	46.4	58.9
Adj. PAT	10.0	15.7	19.9
Adj. EPS (INR)	25.2	44.2	58.9
Adj. EPS Gr. (%)	-8.7	75.5	33.3
BV/Sh. (INR)	193.4	214.5	243.8

Ratios

RoE (%)	13.9	17.1	20.7
RoCE (%)	16.3	16.7	17.9
Payout (%)	60.3	50.0	50.0

Valuations

P/E (x)	66.5	37.9	28.4
P/BV (x)	8.7	7.8	6.9
EV/EBITDA (x)	27.2	18.6	14.9
Div Yield (%)	0.9	1.3	1.8

Shareholding pattern (%)

As On	Jun-25	Mar-25	Jun-24
Promoter	0.0	0.0	0.0
DII	52.3	49.9	47.3
FII	37.4	40.2	41.4
Others	10.3	9.9	11.3

FII Includes depository receipts

CMP: INR1676
TP: INR2,240 (34%)
BUY
Consistent growth delivery
Cash flow conversion a key monitorable

- COFORGE reported strong 1QFY26 revenue growth of 8.0% QoQ in CC terms, above our estimate of 7.0% QoQ CC. The company reported an order intake of USD507m (+61% YoY) in 1Q with five large deals, resulting in a robust 12-month executable order book of USD1.55b. EBIT margin stood at 13.2%, below our estimate of 14%. PAT stood at INR3.1b (up 21.2%/142% QoQ/YoY). M&A expenses stood at INR19m compared to INR148m in 4QFY25.
- The company's revenue/EBIT/adj. PAT grew 8.2%/35.7%/138% YoY. We expect revenue/EBIT/adj. PAT to grow 33.1%/54.1%/61.8% YoY in 2QFY26.
- COFORGE's strong executable order book and resilient client spending across verticals bode well for its organic business. That said, softer cash flow performance during the quarter may exert pressure on the return profile. We now value COFORGE at 38x (vs 40x earlier) FY7 EPS, arriving at a TP of INR 2,240, implying 34% potential upside.

Our view: TTH momentum to sustain on continued Sabre ramp-up

- Consistent revenue traction; Sabre ramp-up gives TTH a solid lift:** COFORGE reported yet another quarter of high single-digit (8%) sequential CC growth. The TTH vertical accounted for ~62% of incremental growth, led by the ongoing ramp-up of the Sabre deal, with further acceleration expected in 2Q. BFSI is also set for a growth rebound next quarter, with the large-deal pipeline remaining robust.
- Deal TCV funnel remains firm:** COFORGE's executable order book for the next 12 months rose 46% YoY to USD1.55b. While deal TCV (ex-Sabre) has remained range-bound at ~USD500m in recent quarters, cross-sell initiatives with Cigniti are beginning to yield results, enabling COFORGE to win large deals. Management aims to close 20 large deals in FY26 (vs. 14 in FY25).
- EBIT margin (ex one-offs) was flat QoQ:** EBIT margins were maintained in 1Q despite ramp-up costs, higher depreciation (AI data centers), and visa costs typically incurred in 1Q. Third party costs (sub-con costs) were 10.5% in 1QFY26 (vs 9.4% in 4QFY25) as deals ramped-up. We expect margins to improve sequentially, driven by the unwinding of ESOP costs. However, we do note that large deal ramp-ups could lead to a flatter margin recovery curve. We estimate FY26 EBIT margin at 13.5% (vs the company's guidance of 14%).
- Free cash flow conversion:** Management reiterated its OCF/EBITDA conversion guidance of 65-70%; we believe this is par for a high-growth IT services company. However, FCF was **negative** this quarter, primarily due to elevated capex related to AI data center investments tied to a large deal. Owning an AI data center asset outright may provide long-term value to COFORGE; however, continued elevated capex could hurt the company's return profile. That said, management expects capex to normalize going forward, with major investments now largely behind.

Abhishek Pathak - Research analyst (Abhishek.Pathak@MotilalOswal.com)

Research analyst: Keval Bhagat (Keval.Bhagat@MotilalOswal.com) | Tushar Dhone (Tushar.Dhone@MotilalOswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report.

 Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.

Valuation and changes to our estimates

- We believe COFORGE's strong executable order book and resilient client spending across verticals bode well for its organic business. Cross-sell opportunities in Cigniti remain highly synergistic for the company. That said, softer cash flow performance during the quarter may exert pressure on the return profile. We have cut our EPS estimates for FY26 by 5%, while largely maintaining our FY27 EPS estimates. We value COFORGE at 38x (earlier 40x) FY27E EPS with a TP of INR2,240, **implying a 34% potential upside. We reiterate our BUY rating on the stock.**

Beat on revenues and miss on margins; TTH leads growth; deal TCV up 61% YoY

- COFORGE's revenue grew 8.0% QoQ CC (est. 7.0% CC). Reported USD growth was 9.6% QoQ.
- Growth was led by the TTH vertical (+31.2% QoQ), followed by Others (Healthcare, Retail, and Hi-Tech), which rose 12.8% QoQ.
- Order intake stood at USD507m (up 61% YoY). The company signed five large deals during the quarter. The 12-month executable order book rose 46.9% YoY to USD1.55b. The company added six new logos during the quarter.
- EBIT margin stood at 13.2%, below our estimate of 14%.
- Adj. EBITDA (pre-RSU) rose 10.5% QoQ/63.8% YoY to INR7.0b.
- Utilization grew 10bp QoQ to 82.1%. Net employee addition stood at 1,164, up 3.5% QoQ. Attrition was up 40bp QoQ at 11.3%.
- PAT stood at INR3.1b (up 21.2%/142% QoQ/YoY). M&A expenses stood at INR19m compared to INR148m in 4QFY25.

Key highlights from the management commentary

- Budget continues to remain similar to last quarter, given the overhang of discussions around macro and tariffs.
- The discretionary nature of spending for the firm remains abated.
- Execution intensity remains a key differentiator, evident across every aspect, including sales, solutions, and M&A, with execution-led metrics becoming central.
- 1) Sustained large deal proposal submissions by the sales team are seen as a better approach with TCV/ACV already signed.
- 2) Execution spans across geo play, vertical play, and partnership scale.
- 3) Hyper-specialization in a few select verticals is essential to create differentiation. AI budgets are increasing at a double-digit rate; industry specialization will remain a key metric in the AI era.
- Real-world AI implementation demands robust infrastructure, data foundation, and AI Ops processors, enabling clients to scale effectively.
- The Sabre deal will continue to ramp up in 2Q; 3Q is expected to witness headcount stabilization. Sales execution rewards are credited only to net-new deals; renewals are excluded from incentive metrics.
- EBIT margin was impacted by amortisation from recent acquisitions and higher depreciation due to AI-powered team investments, large deal ramp-up, and visa costs (typically 1Q-loaded).

Valuation and view

- We believe COFORGE's strong executable order book and resilient client spending across verticals bode well for its organic business. Cross-sell opportunities in Cigniti remain highly synergistic for the company. However, slightly poor cash flow metrics during the quarter weigh on margins due to higher amortization. We have cut our EPS estimates for FY26 by 5%, while largely maintaining our FY27 EPS estimates. We value COFORGE at 38x (earlier 40x) FY27E EPS with a TP of INR2,240, implying a 34% potential upside. We reiterate our BUY rating on the stock.

Quarterly Performance (IND-AS)

Y/E March (Consolidated)	(INR Million)								FY25	FY26E	Est.	Var.					
	FY25				FY26E												
	1Q	2Q	3Q	4Q	1QE	2QE	3QE	4QE									
Rev. (USD m)	286	369	391	404	442	470	494	518	1,445	1,924	438	1.1					
QoQ (%)	2.0	29.0	5.7	3.3	9.6	6.2	5.0	5.0	31.5	33.1	8.5	116bp					
Revenue (INR m)	23,751	30,623	32,581	34,099	36,886	40,762	42,801	44,941	1,20,507	1,65,390	37,450	-1.5					
YoY (%)	6.9	34.5	40.2	47.1	55.3	33.1	31.4	31.8	33.8	37.2	56.0	-69bp					
GPM (%)	32.2	32.4	33.4	34.1	34.1	34.2	33.5	34.2	33.6	34.0	35.0	-90bp					
SGA (%)	13.4	15.9	15.7	15.4	15.0	15.1	15.3	15.3	15.6	15.2	15.3	-30bp					
EBITDA (INRm)	4,275	4,840	5,072	5,761	6,451	7,256	7,362	8,044	19,960	29,113	6,741	-4.3					
EBITDA Margin (%)	18.0	15.8	15.6	16.9	17.5	17.8	17.2	17.9	16.6	17.6	18.0	-51bp					
EBIT (INRm)	3,558	3,597	3,907	4,507	4,859	5,544	5,650	6,269	15,684	22,322	5,243	-7.3					
EBIT Margin (%)	15.0	11.7	12.0	13.2	13.2	13.6	13.2	14.0	13.0	13.5	14.0	-83bp					
Other income	-516	-173	-329	-300	246	-122	-128	-135	-1,080	-140	-112	-319.0					
ETR (%)	34.4	25.5	25.5	22.2	18.2	23.0	23.0	24.0	25.7	22.3	24.5	-25.8					
Minority Interest	-61.0	-314.0	-404.0	-461.0	-390.0	-433.6	-433.6	-433.6	-1,240.0	-1,690.8	-25.7	1419.4					
Reported PAT	1,310	2,021	2,142	2,611	3,174	3,741	3,818	4,229	8,372	14,962	3,848	-17.5					
QoQ (%)	-41.6	54.3	6.0	21.9	21.6	17.8	2.1	10.8			47.4						
YoY (%)	-21.4	11.7	-10.0	16.3	142.3	85.1	78.2	62.0	0.9	78.7	186.4						
Extra-ordinary items	953	290	162	261	749	0	0	0	1,666	1,462	0.0						
Adj. PAT	2,263	2,311	2,304	2,872	3,923	3,741	3,818	4,229	9,750	15,711	3,848.0						
EPS (INR)	4.2	6.0	6.3	7.7	9.4	11.1	11.3	12.5	25.2	44.2	11.3	-17.3					

Key Performance Indicators

Y/E March	FY25					FY26E		FY25
	1Q	2Q	3Q	4Q	1Q			
Revenue (QoQ CC %)	1.6	26.3	8.4	3.4	8.0			
Margins								
Gross Margin	32.2	32.4	33.4	34.1	34.1			33.6
EBIT Margin	15.0	11.7	12.0	13.2	13.2			13.0
Net Margin	5.5	6.6	6.6	7.7	8.6			6.9
Operating metrics								
Headcount	26,612	32,483	33,094	33,497	34,187			33,497
Attrition (%)	11.4	11.7	11.9	10.9	11.3			10.9
Deal Win TCV (USD b)	314	516	501	2,126	507			3,457
Key Verticals (YoY USD %)								
BFS	11.3	23.6	18.3	30.9	30.2			21.3
Insurance	(5.1)	12.3	18.3	11.7	17.7			9.3
Travel and Transport	6.6	30.0	40.8	55.9	88.9			33.2
Key Geographies (YoY USD %)								
North America	9.6	48.2	66.4	64.7	69.5			47.1
Europe	4.2	15.7	18.4	15.3	20.6			13.5



Key highlights from the management commentary

Demand outlook

- Budget continues to remain similar compared to the last quarter, given the overhang of discussions around macro and tariffs.
- The discretionary nature of spending for the firm remains abated.
- Execution intensity remains a key differentiator, evident across every aspect, including sales, solutions, and M&A, with execution-led metrics becoming central.
- 1) Sustained large deal proposal submissions by the sales team are seen as a better approach with TCV/ACV already signed.
- 2) Execution spans across geo play, vertical play, and partnership scale.
- 3) Hyper-specialization in a few select verticals is essential to create differentiation. AI budgets are increasing at a double-digit rate; industry specialization will remain a key metric in the AI era.
- Real-world AI implementation demands robust infrastructure, data foundation, and AI Ops processors, enabling clients to scale effectively.
- The company reported growth of 8.0% QoQ CC. 2H is expected to be much stronger than 1H.
- Organically, 1Q saw 6% CC growth; 2Q is expected to be equally robust.
- The company reported an order intake of USD507m during the quarter; it signed five large deals and added six new logos.
- The 12-month executable order book stood at USD1.55b, up 46.9% YoY.
- 1Q growth was led by large deal ramp-up. The company aims to close 20 large deals in the current fiscal.
- The Sabre deal will continue to ramp up in 2Q; 3Q is expected to see headcount stabilization.
- Sales execution rewards are credited only to net-new deals; renewals are excluded from incentive metrics.
- Growth in the top 6-10 client buckets is expected to resume from 2Q.
- Integration with Cigniti is targeted for completion by December-January.
- **BFSI** reported YoY growth of 32%, with strong traction in large deals. BFSI growth is expected to bounce back in 2Q; pipeline remains strong.
- BFSI clients are under pressure to improve ROE due to macro conditions and higher interest rates.
- The company has seen positive momentum in regulatory compliance, customer retention, and advanced risk management.
- Additionally, it has witnessed strong demand across lending, commercial banking, and regulation-focused services.
- The cloud-native infrastructure has become essential and is non-discretionary for banks.
- The medium-term outlook remains positive; large-deal pipeline remains solid.
- BFSI is expected to remain at ~27% of revenue and continues to pace ahead at the current run-rate.
- **TTH:** The Sabre deal ramp up led growth in 1Q. 2Q is expected to see growth due to a further ramp up.
- The company launched Coforge AgentSphere, a platform with 100+ foundational agents targeting specific industry pain-points across Travel, Financial Services, and Healthcare.
- Net employee addition: 1,164 in the quarter, up 3.5% QoQ.

Margin performance and other comments

- FY26 EBIT margin target: 14% (according to management factsheet).
- The company's focus is shifting from adjusted EBITDA to EBIT margin commentary.
- EBIT margin was impacted by amortisation from recent acquisitions and higher depreciation due to AI-powered team investments, large deal ramp-up, and visa costs (typically 1Q-loaded).
- One-off impact of USD8.4m from AdvantageGo investment was offset by provisions for cybersecurity incident and a one-time employee bonus of USD5-5.5m.
- FCF was negative this quarter due to capex for a data center deal.
- Discounting on long-term contracts: For every USD100 billed, USD90 is booked as revenue and USD10 as other income. This unwinding is treated as accounting notional interest.
- Capex (~USD85m) was largely incurred in 4Q and 1Q—linked to the data center deal (of which USD62m has been completed).
- ESOP costs are expected to decline in coming quarters.
- Ramp-up expenses on large deals typically precede billing. Post 1Q, similar deal ramp-ups will help margin as operating leverage kicks in.
- Wage hikes are scheduled for 3Q and will be offset by lower ESOP costs.
- OCF/EBITDA is expected to remain in the 65-70% range, with the remaining allocated to working capital to support growth.
- Capex levels will taper down to normalized levels going forward.
- Depreciation and amortisation will normalize from here.
- Data center capex: The company owns and controls the asset; it is not client-dedicated.
- FCF for the quarter was weighed down by elevated capex.

Exhibit 1: TTH led growth on the back of deal ramp-up

Verticals (QoQ, USD%)	1QFY23	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26
BFS	9.4	11.1	0.0	4.7	3.1	4.0	3.3	4.3	-0.6	15.4	-1.1	15.4	-1.1
Insurance	-7.7	3.9	-2.9	5.5	4.7	2.3	-1.3	-2.2	-3.9	21.1	4.1	-7.7	1.2
Transportation	-0.9	2.9	1.9	2.3	1.2	2.3	-2.4	-1.5	8.5	24.7	5.7	9.0	31.5
Govt Outside India									9.2	20.4	-4.0	10.8	6.7
Others	8.5	-4.7	8.7	7.0	2.1	0.5	4.0	-30.6	13.3	53.5	17.6	-6.4	12.6

Source: Company, MOFSL.

Exhibit 2: US and APAC contributed to growth

Geography (QoQ, USD%)	1QFY23	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26
US	5.6	3.4	-2.2	3.1	5.8	1.7	-4.3	2.0	10.5	37.5	7.4	0.9	13.6
EMEA	-4.8	7.9	6.7	3.2	0.2	2.8	4.5	-0.1	-3.0	14.3	7.0	-2.7	1.5
APAC	18.7	-11.3	4.9	21.1	-0.6	3.2	15.2	-9.3	-1.4	21.3	-6.7	38.1	13.0

Source: Company, MOFSL

Valuation and view:

- We believe COFORGE's strong executable order book and resilient client spending across verticals bode well for its organic business. Cross-sell opportunities in Cogniti remain highly synergistic for the company. However, slightly poor cash flow metrics during the quarter weigh on margins due to higher amortization. We have cut our EPS estimates for FY26 by 5%, while largely maintaining our FY27 EPS estimates. We value COFORGE at 38x (earlier 40x) FY27E EPS with a TP of INR2,240, implying a 34% potential upside. We reiterate our BUY rating on the stock.

Exhibit 3: Summary of our revised estimates

	Revised		Earlier		Change	
	FY26E	FY27E	FY26E	FY27E	FY26E	FY27E
INR/USD	86.4	86.7	86.4	86.7	0.0%	0.0%
USD Revenue - m	1,924	2,317	1,905	2,306	1.0%	0.5%
Growth (%)	33.1	20.4	31.8	21.0	130bps	-60bps
EBIT margin (%)	13.5	14.0	13.8	14.0	-30bps	0bps
Adj. PAT (INR M)	15,711	19,943	16,606	20,436	-5.4%	-2.4%
EPS	46.4	58.9	48.9	60.2	-5.1%	-2.2%

Source: MOFSL

Exhibit 4: Operating metrics

	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26
Revenue mix Geography-wise (%)									
Americas	49.7	49.4	46.6	47.7	50.8	55.1	56.0	54.7	56.7
EMEA	38.6	38.8	40.0	40.1	37.5	33.8	34.2	32.2	29.8
RoW	11.7	11.8	13.4	12.2	11.6	11.1	9.8	13.1	13.5
Revenue mix Vertical-wise (%)									
BFS	31.1	31.6	32.2	33.7	32.3	29.4	27.5	30.7	27.7
Insurance	22.6	22.6	22.0	21.6	20.0	19.1	18.8	16.8	15.5
Transportation	18.5	18.5	17.8	17.6	18.4	18.1	18.1	19.1	22.9
Manufacturing/Media/Others	27.8	27.3	28.0	19.5	21.3	25.9	28.7	25.9	26.7
Revenue mix (%)									
Top Clients contribution (%)									
Top - 5	25.1	23.5	22.7	23.0	21.0	18.7	19.8	18.0	20.7
Top - 10	37.7	35.2	34.3	34.4	32.9	28.2	30.0	27.7	29.3
Fresh order Intake - USD m									
USA	155	118	110	627	126	245	294	1828	272
EMEA	346	138	172	102	96	184	93	170	140
RoW	30	57	72	46	92	86	114	128	95
Deals signed - USD m	531	313	354	774	314	516	501	2126	507
Executable Order Book (NTM) - USD m	897	935	974	1019	1070	1105	1365	1505	1550
Employee metrics									
Billable Personnel	22762	23131	23107	23243	25037	30434	30981	31354	32013
Sales and Marketing	363	360	368	388	442	575	583	586	594
Others	1099	1147	1132	1095	1133	1474	1530	1557	1580
Total	24224	24638	24607	24726	26612	32483	33094	33497	34187
Utilization	81	80	79.4	81.7	81.6	82.2	81.3	82	82.1
Attrition	13.3	13.0	12.1	11.5	11.4	11.7	11.9	10.9	11.3

Source: Company, MOFSL

Financials and valuations

Income Statement							(INR m)
Y/E March	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Sales	46,628	64,320	80,146	90,089	1,20,507	1,65,390	2,00,916
Change (%)	11.5	37.9	24.6	12.4	33.8	37.2	21.5
Cost of revenue	31,692	43,736	54,059	60,179	80,017	1,09,163	1,33,096
Gross Profit	14,936	20,584	26,087	29,910	40,490	56,227	67,821
SGA expenses	6,545	8,527	11,438	13,694	18,799	25,113	30,137
RSU costs	480	633	587	1,046	1,731	2,000	1,819
EBITDA	7,911	11,424	14,062	15,170	19,960	29,113	35,865
% of Net Sales	17.0	17.8	17.5	16.8	16.6	17.6	17.9
Depreciation	1,836	2,272	2,585	2,972	4,276	6,791	7,827
EBIT	6,075	9,152	11,477	12,198	15,684	22,322	28,038
% of Net Sales	13.0	14.2	14.3	13.5	13.0	13.5	14.0
Other Income	113	-266	-630	-1,153	-1,080	-140	-522
PBT	6,188	8,886	10,847	11,045	14,604	22,182	27,516
Tax	1,302	1,468	2,208	2,209	3,326	4,781	6,879
Rate (%)	21.0	16.5	20.4	20.0	22.8	21.6	25.0
Extraordinary Items	226	269	1,188	261	1,666	749	0
Minority Interest	104	530	513	276	1,240	1,691	694
Adjusted PAT	4,782	6,888	8,126	8,560	10,038	15,711	19,943
Change (%)	1.4	44.0	18.0	5.3	17.3	56.5	26.9

Balance Sheet							(INR m)
Y/E March	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Share Capital	606	609	611	618	669	669	669
Reserves	24,055	26,722	30,214	35,648	63,123	71,220	81,060
Net Worth	24,661	27,331	30,825	36,266	63,792	71,889	81,729
Loans	5	3,365	3,382	3,399	67	67	67
Minority Interest	0	983	874	1,003	19,498	19,498	19,498
Other liabilities	2,043	6,073	4,360	5,094	13,750	18,871	22,925
Capital Employed	26,709	37,752	39,441	45,762	97,107	1,10,326	1,24,218
Net Block	3,902	4,452	4,455	4,470	7,682	5,249	1,988
CWIP	2	86	46	232	24	24	24
Intangibles	5,690	14,821	16,299	16,133	49,726	48,368	46,802
Investments	0	0	0	0	0	0	0
Deferred tax assets	4,245	7,976	9,970	14,217	19,860	27,257	33,112
Curr. Assets	21,295	22,209	26,064	26,025	43,508	62,046	79,103
Debtors	8,895	13,894	16,131	18,039	25,771	30,812	37,431
Cash & Bank Balance	7,999	4,468	5,699	3,213	7,956	18,679	26,921
Investments	247	67	88	139	2,333	2,333	2,333
Other Current Assets	4,154	3,780	4,146	4,634	7,448	10,222	12,418
Current Liab. & Prov	8,425	11,792	17,393	15,315	27,375	36,301	40,492
Trade payables	3,398	6,160	6,481	8,062	9,883	18,546	22,529
Other liabilities	4,802	5,316	10,552	6,836	16,786	16,786	16,786
Provisions	225	316	360	417	706	969	1,177
Net Current Assets	12,870	10,417	8,671	10,710	16,133	25,746	38,611
Application of Funds	26,709	37,752	39,441	45,762	97,107	1,10,326	1,24,218

Financials and valuations

Ratios

Y/E March	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
EPS	15.5	22.2	26.1	27.6	25.2	44.2	58.9
Cash EPS	20.7	28.6	30.6	37.5	38.1	64.3	82.1
Book Value	81.4	89.7	101.0	122.5	193.4	214.5	243.8
DPS	4.1	10.4	12.8	15.2	15.2	22.1	29.5
Payout %	26.5	46.9	49.0	55.1	60.3	50.0	50.0
Valuation (x)							
P/E	108.3	75.5	64.2	60.7	66.5	37.9	28.4
Cash P/E	81.0	58.5	54.8	44.7	44.0	26.1	20.4
EV/EBITDA	63.1	44.6	36.2	32.7	27.2	18.6	14.9
EV/Sales	10.7	7.9	6.4	5.5	4.5	3.3	2.7
Price/Book Value	20.6	18.7	16.6	13.7	8.7	7.8	6.9
Dividend Yield (%)	0.2	0.6	0.8	0.9	0.9	1.3	1.8
Profitability Ratios (%)							
RoE	19.7	26.0	27.1	24.1	13.9	17.1	20.7
RoCE	18.0	23.7	23.7	22.8	16.3	16.7	17.9
Turnover Ratios							
Debtors (Days)	68	65	68	69	66	62	62
Fixed Asset Turnover (x)	11.8	15.4	18.0	20.2	19.8	25.6	55.5

Cash Flow Statement

Y/E March	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
CF from Operations	7,121	9,089	10,532	11,834	15,060	22,337	27,741
Cash for Working Capital	502	-1,433	-1,027	-2,800	-2,689	-1,165	-6,424
Net Operating CF	7,623	7,656	9,505	9,034	12,371	21,171	21,317
Net Purchase of FA	-757	-1,475	-1,537	-2,598	-5,572	-3,000	-3,000
Free Cash Flow	6,866	6,181	7,968	6,436	6,799	18,171	18,317
Net Purchase of Invest.	-1,597	-8,089	-1,179	120	-18,911	0	0
Net Cash from Invest.	-2,354	-9,564	-2,716	-2,478	-24,483	-3,000	-3,000
Proceeds from Equity	18	51	18	-3,516	21,831	0	0
Proceeds from LTB/STB	-697	2,139	-1,315	-573	19	33	-103
Dividend Payments	-4,852	-3,748	-4,285	-4,781	-5,097	-7,481	-9,972
Cash Flow from Fin.	-5,531	-1,558	-5,582	-8,870	16,753	-7,448	-10,075
Net Cash Flow	-262	-3,466	1,207	-2,314	4,641	10,723	8,242
Exchange difference	66	-65	24	-172	102	0	0
Opening Cash Bal.	8,194	7,998	4,467	5,698	3,212	7,955	18,678
Add: Net Cash	-196	-3,531	1,231	-2,486	4,743	10,723	8,242
Closing Cash Bal.	7,998	4,467	5,698	3,212	7,955	18,678	26,920

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	> - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures:

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf>

Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

MOFSL, its associates, Research Analyst or their relatives may have any financial interest in the subject company. MOFSL and/or its associates and/or Research Analyst or their relatives may have actual beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance. MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may have any other potential conflict of interests at the time of publication of the research report or at the time of public appearance, however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

In the past 12 months, MOFSL or any of its associates may have:

- a) received any compensation/other benefits from the subject company of this report
- b) managed or co-managed public offering of securities from subject company of this research report,
- c) received compensation for investment banking or merchant banking or brokerage services from subject company of this research report,
- d) received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company of this research report.

- MOFSL and its associates have not received any compensation or other benefits from the subject company or third party in connection with the research report.
- Subject Company may have been a client of MOFSL or its associates during twelve months preceding the date of distribution of the research report.
- Research Analyst may have served as director/officer/employee in the subject company.
- MOFSL and research analyst may engage in market making activity for the subject company.

MOFSL and its associate company(ies), and Research Analyst and their relatives from time to time may have:

- a) a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein.
- (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures. To enhance transparency, MOFSL has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report. MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Disclosure of Interest Statement	Coforge
Analyst ownership of the stock	No

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to subject company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal Capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Financial Services Limited (SEBI Reg No. INH000000412) has an agreement with Motilal Oswal Capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

MOTILAL Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and

services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets Singapore Pte Ltd ("MOCMSPL") (Co. Reg. NO. 201129401Z) which is a holder of a capital markets services license and an exempt financial adviser in Singapore. Persons in Singapore should contact MOCMSPL in respect of any matter arising from, or in connection with this report/publication/communication. This report is distributed solely to persons who qualify as "Institutional Investors", of which some of whom may consist of "accredited" institutional investors as defined in section 4A(1) of the Securities and Futures Act of Singapore .Accordingly, if a Singapore person is not, or ceases to be, such an investor, they must immediately discontinue any use of this Report and inform MOCMSPL .

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alterations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN : 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.